Skip to main content
Caplight Logo









Brink Therapeutics

Brink Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.brinktx.com/

Last Round

Seed

Apr 16, 2025

Total Funding Raised

$3.99M

Company Overview

Brink Therapeutics is a biotechnology company developing a gene-editing platform centered on the discovery and development of therapeutic recombinases for cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

gene editing platformprogrammable integrasesnuclease-free gene editingCRISPR alternativelarge payload gene therapygenerative AI protein designcell and gene therapygenomic integrationCAR-T cell therapyAI drug discoveryin vivo gene therapygenerative biologydirected evolutionmonogenic rare diseaseshigh-throughput screeningplatform licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Brink Therapeutics Comparables

Compare Brink Therapeutics with similar companies based on industry and business-model similarity.

Brink Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seamless Therapeutics
85%
IntegraTherapeutics
81%
Komo Biosciences
81%

Brink Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 16, 2025

Key People

Founding team and executive leadership

Harry Kemble

CTO & Co-Founder

Founding Team

Jonathan Naccache

CEO & Co-founder

Founding Team

Brink Therapeutics Investors

Notable investors and investment history

Brink Therapeutics investors
InvestorRounds
Kima VenturesSeed
Plug and Play Tech CenterSeed
BreegaSeed
Kurma PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Grew 38% QoQ, from 8 to 11 employees.

  • Nov 11, 2025

    Grew 100% QoQ from 4 to 8 employees.

Brink Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Brink Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Brink Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range12
Year Founded2024
Last FundingApr 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?